Online Ketamine Treatment Available in: AZ, CA, CO, FL, GA, NY, OR, TX, and WA.
Online Ketamine Treatment Available in: AZ, CA, CO, FL, GA, NY, OR, TX, and WA.
Millions of people are now taking GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) for weight management and type 2 diabetes. But patients and clinicians are noticing something unexpected: some people report improvements in mood, reduced anxiety, and even decreased cravings for alcohol and other substances. Is this a placebo effect, a downstream benefit of weight loss, or something the drugs are doing directly in the brain?
Emerging research suggests the answer may be all three — and that GLP-1 receptors in the brain play a more significant role in mental health than previously understood.
GLP-1 (glucagon-like peptide-1) is a hormone naturally produced in the gut after eating. It signals the pancreas to release insulin, slows gastric emptying, and reduces appetite. GLP-1 receptor agonists are synthetic versions of this hormone that last much longer than the natural version.
The major GLP-1 medications currently available include:
What makes these drugs relevant to mental health is that GLP-1 receptors are not limited to the gut and pancreas. They are found throughout the brain — in the hippocampus, amygdala, hypothalamus, and prefrontal cortex — regions directly involved in mood regulation, fear processing, memory, and reward.
A large retrospective cohort study published in 2024 analyzed electronic health records of over 1.6 million patients with type 2 diabetes. Researchers found that patients taking semaglutide had a significantly lower incidence of new depression diagnoses compared to those on other diabetes medications. The effect persisted even after controlling for weight loss, suggesting a potential direct neurological mechanism.
Preclinical studies support this finding. Animal models have demonstrated that GLP-1 receptor activation in the brain increases BDNF (brain-derived neurotrophic factor) — the same neuroplasticity protein that ketamine therapy is believed to upregulate. GLP-1 agonists have also been shown to reduce neuroinflammation, a factor increasingly implicated in treatment-resistant depression.
A 2023 study by Mansur et al. published in Obesity found that semaglutide improved cognitive function and reduced depressive symptoms in patients with obesity, independent of the magnitude of weight loss.
The relationship between GLP-1 agonists and anxiety is more nuanced. Some patients report reduced anxiety while taking these medications, which researchers attribute to several possible mechanisms:
However, it is important to note that some patients report increased anxiety, particularly in the early weeks of treatment. The FDA has received reports of suicidal ideation in a small number of patients, though large-scale analyses have not established a causal link. The European Medicines Agency reviewed the data in 2023 and concluded there was no evidence of increased suicide risk.
Perhaps the most intriguing mental health finding involves substance use. Anecdotal reports from patients and clinicians describe reduced cravings for alcohol, nicotine, and even compulsive behaviors while on GLP-1 agonists.
This aligns with neuroscience. GLP-1 receptors are present in the mesolimbic reward pathway — the same dopamine-driven circuit involved in addiction. Preclinical studies have shown that GLP-1 agonists reduce alcohol consumption in rodent models, and a 2023 retrospective analysis found lower rates of alcohol use disorder diagnoses among patients prescribed semaglutide compared to matched controls.
Clinical trials are now underway to formally test semaglutide for alcohol use disorder, with the University of North Carolina and other institutions leading Phase 2 studies. Results are expected in 2025-2026.
Tirzepatide activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. GIP receptors are also found in the brain, and early research suggests the dual mechanism may produce different neuropsychiatric effects than pure GLP-1 agonists. However, mental health data specific to tirzepatide is still limited, and most published findings focus on semaglutide and liraglutide.
For patients with comorbid obesity and depression — a very common overlap — GLP-1 agonists may offer a dual benefit that traditional antidepressants do not. SSRIs frequently cause weight gain, which worsens metabolic health and can worsen depression in a vicious cycle. A medication that addresses both weight and mood simultaneously could represent a paradigm shift.
At Isha Health, we see many patients whose depression is intertwined with metabolic health, chronic pain, and inflammation. While we specialize in ketamine-assisted therapy, we recognize that mental health treatment is not one-size-fits-all. Understanding how medications like GLP-1 agonists interact with mood and brain chemistry helps us provide more comprehensive guidance to our patients.
It is worth noting that GLP-1 agonists are not approved for the treatment of depression, anxiety, or any psychiatric condition. Any mental health benefits observed are secondary effects, and these medications should not be prescribed specifically for mood disorders outside of clinical trials.
If you are currently taking a GLP-1 agonist and notice changes in your mood — positive or negative — it is important to discuss this with your prescriber. These medications affect brain chemistry in ways that are still being studied, and your clinician should be aware of any neuropsychiatric changes.
For patients with treatment-resistant depression who are also considering weight management, the emerging GLP-1 research adds another dimension to treatment planning. This does not replace proven approaches like ketamine therapy, psychotherapy, or established antidepressants — but it may complement them.
If you experience worsening depression, anxiety, or suicidal thoughts while on any medication, seek medical attention immediately. Call 988 (Suicide and Crisis Lifeline) or go to your nearest emergency department.
GLP-1 receptor agonists appear to have meaningful effects on brain chemistry beyond metabolism. Early evidence suggests potential benefits for depression, anxiety, and addiction — driven by BDNF upregulation, neuroinflammation reduction, and reward pathway modulation. However, this research is still in its early stages, and these medications are not approved for psychiatric use. Patients and clinicians should monitor mood changes and await the results of ongoing clinical trials before drawing conclusions.
Mansur RB et al. "Semaglutide improves cognitive function and depressive symptoms in patients with obesity." Obesity. 2023.
Wang W et al. "GLP-1 receptor agonists and risk of depression: a systematic review and meta-analysis of real-world evidence." Diabetes Care. 2024.
If you're considering ketamine therapy, Isha Health offers physician-led at-home treatment via telemedicine in California, New York, Texas, Florida, Colorado, Arizona, Georgia, Oregon, and Washington. No in-person visit required.
